Forian INC

Forian Inc. announced the successful completion of a tender offer and subsequent merger, resulting in the company becoming a wholly owned subsidiary of 2025 Acquisition Company, LLC, and its common stock delisting from the Nasdaq Stock Market.

Forian Inc. has entered into a definitive agreement to be acquired by an entity affiliated with a consortium of investors led by Chairman and CEO Max Wygod in an all-cash transaction valued at approximately $68 million.

Forian Inc. announced its fourth quarter and full year 2025 financial results, highlighting significant revenue growth and a reduced annual net loss, alongside ongoing discussions for a potential take-private transaction.

Forian Inc. has successfully completed its redomiciliation from Delaware to Maryland, a move approved by stockholders, effective January 9, 2026.

Forian Inc. announced robust third-quarter 2025 financial results, showcasing significant revenue growth and improved Adjusted EBITDA, while reconfirming its full-year 2025 outlook.

Forian Inc. announced its Board received an unsolicited, non-binding proposal from a group led by its CEO to take the company private at $2.10 per share.

Forian Inc. announced significant revenue growth and a narrower net loss for the third quarter and nine months ended September 30, 2025, driven by the Kyber acquisition and organic growth.

Forian Inc. reported a significant turnaround to net income in Q2 2025, driven by strong revenue growth from the Kyber acquisition and improved operational efficiency, despite ongoing vendor data challenges.

Forian Inc. saw a revenue increase in Q1 2025, primarily due to the acquisition of Kyber Data Science and organic growth in its information products.

Forian Inc. reported a decrease in revenue for the third quarter of 2024, alongside a net loss, as the company continues its transition to focus on healthcare and life sciences analytics.

Forian Inc. reported a slight decrease in revenue and an increased operating loss for the second quarter of 2024, compared to the same period last year.

Forian Inc. reported a slight revenue increase but a net loss for the first quarter of 2024, as it continues its transition to focus on healthcare and life sciences analytics.

Forian Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.

Forian Inc. announced a significant increase in revenue and improved net loss for the fiscal year ended December 31, 2025, driven by organic growth and strategic acquisitions.

Forian Inc.'s 10-K filing reveals restated financial statements for 2023 due to revenue recognition errors and identifies material weaknesses in internal controls over financial reporting.

Forian Inc.'s 2023 annual report details a strategic shift towards healthcare analytics, marked by the divestiture of its cannabis-related businesses and a focus on data-driven solutions.

Director Shahir Kassam-Adams reports the disposal of all equity holdings in Forian Inc. following the company's acquisition.

Executive Chairman and CEO Max C. Wygod reports the completion of the merger of Forian Inc. into a subsidiary of 2025 Acquisition Company, LLC.

Forian Inc. has been acquired by 2025 Acquisition Company, LLC following the completion of a tender offer and merger.

Director Jennifer Hajj reports the disposal of all equity holdings following the completion of Forian Inc.'s acquisition by Parent.

Director Mark J. Adler reports the disposal of all equity holdings following the completion of Forian Inc.'s acquisition by 2025 Acquisition Company, LLC.

CFO Michael Vesey reports the disposition of all common stock and cancellation of stock options following the completion of Forian Inc.'s merger.

Forian Inc. seeks stockholder approval to redomicile from Delaware to Maryland, a move intended to facilitate a potential take-private offer and other strategic transactions.

Forian Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Forian Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on director elections, an amendment to the equity incentive plan, and ratification of the independent accounting firm.

Forian Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Forian Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Major shareholders of Forian Inc. have contributed 21,991,929 shares to 2025 Acquisition Company, LLC in a tax-deferred reorganization.

A group of investors in Forian Inc. has expanded its membership and entered into a contribution agreement to consolidate 21,991,929 shares into a single acquisition vehicle.

A consortium led by Max Wygod has entered into a definitive agreement to acquire Forian Inc. via a tender offer and subsequent merger at $2.17 per share in cash.

Forian Inc. has entered into a definitive merger agreement with an affiliate of Max Wygod to be acquired in an all-cash transaction valued at $2.17 per share.

Forian Inc. has signed a confidentiality agreement with 2025 Acquisition Corporation to facilitate evaluation of a possible negotiated transaction, including a potential acquisition.

Forian Inc. has entered into a confidentiality agreement with 2025 Acquisition Corporation, an affiliate of major shareholder Max Wygod, to facilitate evaluation of a possible negotiated transaction.

Larry N. Feinberg and affiliated Oracle entities have filed an Amendment No. 3 to Schedule 13G, indicating they no longer collectively hold a beneficial ownership stake of 5% or more in Forian Inc. as of December 31, 2024.

Thomas J. Coleman has filed an Amendment No. 1 to Schedule 13G, disclosing a beneficial ownership of 2.9% of Forian Inc.'s common stock as of December 31, 2024.